VectorY raises $38M to develop Alzheimer's, ALS gene therapies

VectorY Therapeutics has raised €31 million ($38 million) to fund preclinical work on gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease. Forbion led the seed financing in the Dutch developer of vectorized antibodies with the support of other investors including Eli Lilly.